Literature DB >> 22955010

The effect of delay time between primary melanoma biopsy and sentinel lymph node dissection on sentinel node status, recurrence, and survival.

Brian M Parrett1, Neil A Accortt, Rui Li, Amarjit S Dosanjh, Suresh Thummala, Raj Kullar, James E Cleaver, Mohammed Kashani-Sabet, Stanley P L Leong.   

Abstract

For primary melanoma, there is a delay between the initial skin biopsy and sentinel lymph node dissection, which may cause anxiety for the patient. The consequences of this delay on disease progression are unknown. The goal of this study was to determine whether delay time for sentinel node dissection from the initial cutaneous melanoma biopsy affects patient outcomes. A retrospective analysis of 492 patients with melanoma who underwent a sentinel node dissection between 1993 and 1999 was carried out. The endpoints assessed were sentinel node tumor status, recurrence, and mortality. Time to sentinel node dissection was compared between patients with positive and negative sentinel nodes. Long-term survival and recurrence were evaluated in relation to the time between the cutaneous biopsy and the sentinel node dissection (delay time), comparing less than 40 days with at least 40 days. In total, 15.9% of patients had positive sentinel nodes. The median follow-up was 11.7 years. Positive sentinel node patients had a median delay of 35 days between the primary melanoma biopsy and the sentinel node dissection compared with 41 days for negative sentinel node patients (P=0.5). Kaplan-Meier survival curves showed that a delay time of less than 40 days versus at least 40 days was not related to recurrence of melanoma (log-rank P=0.13) or overall survival (log-rank P=0.14). On multivariate analysis of age, thickness, ulceration, and sentinel node status, there was no difference in disease-free survival (P=0.58) or overall survival (P=0.53) between the less than 40 days and the at least 40 days groups. A modest delay in sentinel node dissection from the initial melanoma biopsy does not adversely affect sentinel node status, recurrence, nor survival.

Entities:  

Mesh:

Year:  2012        PMID: 22955010     DOI: 10.1097/CMR.0b013e32835861f6

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  7 in total

1.  Impact of Time Between Diagnosis and SLNB on Outcomes in Cutaneous Melanoma.

Authors:  Daniel W Nelson; Stacey Stern; David E Elashoff; Robert Elashoff; John F Thompson; Nicola Mozzillo; Omgo E Nieweg; Harald J Hoekstra; Alistair J Cochran; Mark B Faries
Journal:  J Am Coll Surg       Date:  2017-06-28       Impact factor: 6.113

2.  Effect of time to sentinel-node biopsy on the prognosis of cutaneous melanoma.

Authors:  Antonio Tejera-Vaquerizo; Eduardo Nagore; Susana Puig; Caroline Robert; Philippe Saiag; Paula Martín-Cuevas; Elena Gallego; Enrique Herrera-Acosta; José Aguilera; Josep Malvehy; Cristina Carrera; Andrea Cavalcanti; Ramón Rull; Antonio Vilalta-Solsona; Emilie Lannoy; Celine Boutros; Naima Benannoune; Gorana Tomasic; Philippe Aegerte; Sergi Vidal-Sicart; Josep Palou; L Lúcia Alos; Celia Requena; Víctor Traves; Ángel Pla; Isidro Bolumar; Virtudes Soriano; Carlos Guillén; Enrique Herrera-Ceballos
Journal:  Eur J Cancer       Date:  2015-06-10       Impact factor: 9.162

3.  Using a Clinicopathologic and Gene Expression (CP-GEP) Model to Identify Stage I-II Melanoma Patients at Risk of Disease Relapse.

Authors:  Evalyn E A P Mulder; Iva Johansson; Dirk J Grünhagen; Dennie Tempel; Barbara Rentroia-Pacheco; Jvalini T Dwarkasing; Daniëlle Verver; Antien L Mooyaart; Astrid A M van der Veldt; Marlies Wakkee; Tamar E C Nijsten; Cornelis Verhoef; Jan Mattsson; Lars Ny; Loes M Hollestein; Roger Olofsson Bagge
Journal:  Cancers (Basel)       Date:  2022-06-09       Impact factor: 6.575

4.  Malignant melanoma: factors affecting the surgical interval from excision biopsy to definitive surgical management.

Authors:  M R Boland; R S Prichard; G A Bass; Z Al-Hilli; A Levendale; D Gibbons; K Sheahan; B Kirby; E W McDermott; D Evoy
Journal:  Ir J Med Sci       Date:  2014-06-11       Impact factor: 1.568

5.  Determination of the impact of melanoma surgical timing on survival using the National Cancer Database.

Authors:  Ruzica Z Conic; Claudia I Cabrera; Alok A Khorana; Brian R Gastman
Journal:  J Am Acad Dermatol       Date:  2017-10-17       Impact factor: 11.527

6.  What is Elective Oncologic Surgery in the Time of COVID-19? A Literature Review of the Impact of Surgical Delays on Outcomes in Patients with Cancer.

Authors:  Denise Garcia; Julie B Siegel; David A Mahvi; Biqi Zhang; David M Mahvi; E Ramsay Camp; Whitney Graybill; Stephen J Savage; Antonio Giordano; Sara Giordano; Denise Carneiro-Pla; Mahsa Javid; Aaron P Lesher; Andrea Abbott; Nancy Klauber DeMore
Journal:  Clin Oncol Res       Date:  2020-06-26

7.  Validation of a clinicopathological and gene expression profile model for sentinel lymph node metastasis in primary cutaneous melanoma.

Authors:  E E A P Mulder; J T Dwarkasing; D Tempel; A van der Spek; L Bosman; D Verver; A L Mooyaart; A A M van der Veldt; C Verhoef; T E C Nijsten; D J Grunhagen; L M Hollestein
Journal:  Br J Dermatol       Date:  2020-11-02       Impact factor: 9.302

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.